T1	Participants 935 981	204 patients with probable Alzheimer's disease
T2	Participants 1020 1214	136 patients were eligible for the according-to-protocol analysis of efficacy, 167 subjects for the intention-to-treat analysis of efficacy, and 181 patients were included in the safety analysis
